These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 15254058

  • 1. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM.
    J Clin Oncol; 2004 Jul 15; 22(14):2891-900. PubMed ID: 15254058
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
    Hutson TE, Molto L, Mekhail T, Elson P, Finke J, Tannenbaum C, Borden E, Dreicer R, Olencki T, Bukowski RM.
    Clin Cancer Res; 2003 Apr 15; 9(4):1354-60. PubMed ID: 12684404
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
    George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R, Bukowski RM.
    Cancer Chemother Pharmacol; 2008 Jul 15; 62(2):347-54. PubMed ID: 17909807
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.
    J Clin Oncol; 2003 Jul 01; 21(13):2564-73. PubMed ID: 12829677
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
    Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE.
    J Clin Oncol; 2005 Dec 01; 23(34):8835-44. PubMed ID: 16314644
    [Abstract] [Full Text] [Related]

  • 6. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
    Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C.
    J Clin Oncol; 2009 Jul 20; 27(21):3496-502. PubMed ID: 19433681
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, Coudert B, Négrier S, Groupe Français d'Immunothérapie.
    Cancer; 2002 Dec 01; 95(11):2324-30. PubMed ID: 12436438
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB.
    Clin Cancer Res; 2000 May 01; 6(5):1678-92. PubMed ID: 10815886
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.
    J Clin Oncol; 1996 Aug 01; 14(8):2234-41. PubMed ID: 8708712
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 01; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 11. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM.
    J Interferon Cytokine Res; 2001 Apr 01; 21(4):257-63. PubMed ID: 11359657
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ.
    J Clin Oncol; 2007 Aug 01; 25(22):3288-95. PubMed ID: 17664476
    [Abstract] [Full Text] [Related]

  • 13. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE.
    J Natl Cancer Inst; 2004 Sep 01; 96(17):1331-42. PubMed ID: 15339971
    [Abstract] [Full Text] [Related]

  • 14. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 01; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
    McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.
    J Clin Oncol; 2005 Jan 01; 23(1):133-41. PubMed ID: 15625368
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.
    Clin Cancer Res; 2007 Mar 15; 13(6):1801-9. PubMed ID: 17363536
    [Abstract] [Full Text] [Related]

  • 17. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J, Subcutaneous Administration Propeukin Program Cooperative Group.
    J Clin Oncol; 2003 Nov 01; 21(21):3987-94. PubMed ID: 14581421
    [Abstract] [Full Text] [Related]

  • 18. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
    Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL.
    BMC Cancer; 2006 Feb 27; 6():44. PubMed ID: 16504154
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L.
    J Clin Oncol; 2001 Mar 01; 19(5):1312-9. PubMed ID: 11230473
    [Abstract] [Full Text] [Related]

  • 20. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.
    J Clin Oncol; 2007 Sep 01; 25(25):3958-64. PubMed ID: 17761980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.